Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT).

T S Armstrong¹, T Mendoza, I Gning

¹The University of Texas Health Science Center at Houston, School of Nursing, Houston, Texas 77030, USA. Tsarmstr@mdanderson.org

Journal of Neuro-Oncology

|April 7, 2006

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

E_N_T_R_O_P_Y: Monocentric analysis of rectal cancer radio-chemotherapy treatment in patients of young age.

Clinical and translational radiation oncology·2025

Same author

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study.

The Lancet. Rheumatology·2024

Same author

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance.

The Lancet. Rheumatology·2024

Same author

Development of BNBSL: A β-ν spectra library for spectrometry applications.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2023

Same author

Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.

Lancet (London, England)·2021

Same author

Correction to: Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD.

Dermatology and therapy·2021

A new tool, the M.D. Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT), reliably measures symptoms in primary brain tumor patients. This validated instrument aids in tracking symptoms and evaluating treatments.

Area of Science:

Neuro-oncology
Symptom Science
Clinical Assessment

Background:

Symptom occurrence predicts outcomes in solid tumors.
Primary brain tumor patients experience unique neurologic symptoms.
No existing instrument measures both cancer and neurologic symptoms.

Purpose of the Study:

To evaluate the reliability and validity of the M.D. Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT).
To assess the MDASI-BT's utility in primary brain tumor patients.

Main Methods:

201 primary brain tumor patients participated.
Data collected included demographics, clinical factors, and MDASI-BT scores.
Reliability and validity of the MDASI-BT were evaluated.

Related Experiment Videos

Main Results:

The 22-item MDASI-BT demonstrated high internal consistency (0.91).
MDASI-BT items explained 56% of symptom severity variability.
The instrument was sensitive to disease severity, performance status, and tumor recurrence.

Conclusions:

The 22-item MDASI-BT is a valid and reliable instrument for primary brain tumor patients.
This tool can identify symptom occurrence across the disease trajectory.
The MDASI-BT can evaluate symptom management interventions.